S
Suzanne Russo
Researcher at East Carolina University
Publications - 10
Citations - 186
Suzanne Russo is an academic researcher from East Carolina University. The author has contributed to research in topics: Cancer & Gemcitabine. The author has an hindex of 6, co-authored 10 publications receiving 179 citations. Previous affiliations of Suzanne Russo include Wake Forest Baptist Medical Center.
Papers
More filters
Journal ArticleDOI
Emerging MEK inhibitors
James A. McCubrey,Linda S. Steelman,Steven L. Abrams,William H. Chappell,Suzanne Russo,Roger Ove,Michele Milella,Agostino Tafuri,Paolo Lunghi,Antonio Bonati,Franca Stivala,Ferdinando Nicoletti,Massimo Libra,Alberto M. Martelli,Giuseppe Montalto,Melchiorre Cervello +15 more
TL;DR: This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series.
Journal ArticleDOI
Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer.
A. William Blackstock,Glenn J. Lesser,June Fletcher-Steede,L. Douglas Case,Robert W. Tucker,Suzanne Russo,Douglas R. White,Antonius A. Miller +7 more
TL;DR: In this article, the maximum tolerated dose (MTD) and dose-limiting toxicity of twice-weekly gemcitabine and concurrent thoracic radiation in patients with Stage IIIa/IIIb non-small-cell lung cancer (NSCLC) were studied.
Journal ArticleDOI
Emerging Raf inhibitors.
James A. McCubrey,Linda S. Steelman,Steven L. Abrams,William H. Chappell,Suzanne Russo,Roger Ove,Michele Milella,Agostino Tafuri,Paolo Lunghi,Antonio Bonati,Franca Stivala,Ferdinando Nicoletti,Massimo Libra,Alberto M. Martelli,Giuseppe Montalto,Melchiorre Cervello +15 more
TL;DR: Targeting of Raf which could control abnormal proliferation in cancer and other proliferative diseases is discussed and the rationales for approaches combining Raf inhibitors and chemotherapeutic drugs are discussed.
Journal ArticleDOI
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines
William H. Chappell,Saverio Candido,Stephen L. Abrams,Suzanne Russo,Roger Ove,Alberto M. Martelli,Lucio Cocco,Giulia Ramazzotti,Melchiorre Cervello,Giuseppe Montalto,Linda S. Steelman,Xiaohong Leng,Ralph B. Arlinghaus,Massimo Libra,James A. McCubrey +14 more
TL;DR: The data indicate that prostate cancer growth, progression and sensitivity to chemotherapeutic drugs are regulated in part by NGAL and may involve complex interactions between NGAL, MMP9, NF-κB and p53.
Journal ArticleDOI
Multidisciplinary treatment of resectable rectal cancer
TL;DR: Evidence is identified that influences current practices in the multidisciplinary treatment and shapes future directions in the treatment of resectable rectal cancer and criteria for patient selection are being re-evaluated to determine the relative benefit of modern treatments, so that it may better tailor adjuvant therapy recommendations to be patient-specific.